Compare StocksMRNA vs TXN

Moderna, Inc. (MRNA) vs Texas Instruments Incorporated (TXN): Which Is the Better Buy in 2026?

As of 2026-09-17, MRNA is overvalued at $156, with a DCF intrinsic value of $67 and a margin of safety of -135%. TXN is undervalued at $257, with an intrinsic value of $365 and a margin of safety of 29%. Of the two, TXN has the wider margin of safety.

MRNA
Moderna, Inc.
$156.43
VS
TXN
Texas Instruments Incorporated
$257.38

Rewards

MRNA
    TXN
    • Texas Instruments Incorporated has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
    • Return on equity has consistently exceeded 20% over 4 years, indicating efficient use of shareholder capital.
    • PEG ratio of 0.94 suggests the stock is undervalued relative to its growth rate — paying less than 1x for each unit of earnings growth.

    Risks

    MRNA
    • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of -66.0% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
    TXN
    • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
    • FCF yield of 1.5% is below 3%, meaning the market is pricing in substantial future growth to justify the current price.
    • Trailing P/E of 39.2x is 45% above the historical average of 27.1x — the stock trades at a premium to its own history.

    Key Valuation Metrics

    Learn more →
    MRNA
    TXN
    Valuation
    $299.25M
    Free Cash Flow
    $3.55B
    0.48%
    FCF Yield
    1.51%
    N/A
    Trailing P/E
    39.18
    -35.00
    Forward P/E
    24.18
    Quality & Moat
    -122.02%
    ROIC
    20.41%
    -39.00%
    ROE
    35.18%
    -66.02%
    Gross Margin
    58.33%
    N/A
    PEG Ratio
    0.94
    Balance Sheet Safety
    Net cash
    Net Debt / Equity
    0.39
    N/A
    Interest Coverage
    N/A
    N/A
    Net Debt / EBITDA
    0.74
    0.00%
    Dividend Yield
    2.18%
    MRNA: 2Ties: 1TXN: 6
    MRNATXN

    Historical Fundamentals

    Learn more →
    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    TXN

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    TXN
    $3.91
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $1.96B
    Δ Market Cap
    +$7.67B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    MRNA
    135.0% Overvalued
    Price is 135.0% above estimated fair value
    Current Price: $156.43
    Fair Value: $66.58
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    TXN
    18.5% Margin of Safety
    Price is 18.5% below estimated fair value
    Current Price: $257.38
    Fair Value: $315.99
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    MRNA

    What growth rate is the market pricing in at $156?

    +39.7%
    Market-Implied FCF Growth Rate

    Market pricing in significantly higher growth than history — aggressive.

    TXN

    What growth rate is the market pricing in at $257?

    +19.8%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +24.5%

    The market implies +19.8% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +24.5%, reflecting heavy growth investment.

    Economic Moat Score

    Learn more →
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    TXN
    48/100
    Narrow Moat
    70+ Wide · 40-69 Narrow · <40 None

    Narrow moat with roic consistency as the key competitive advantage. Improving reinvestment efficiency would strengthen the moat.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    TXN
    -2.67
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    MRNA
    Insiders 7.3%Institutions 80.4%Retail & Other 12.2%
    No. of Institutional Holders1,097
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    TXN
    Insiders 0.3%Institutions 91.7%Retail & Other 8.1%
    No. of Institutional Holders3,671
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    TXN
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    MRNA
    5
    Sells (3M)
    12
    Sells (12M)
    Total value (12M): $63.50M
    HOGE STEPHEN
    President
    $11.69M
    @ $145.10 · 2026-09-15
    MOCK JAMES M
    Chief Financial Officer
    $4.69M
    @ $134.49 · 2026-09-10
    KLINGER SHANNON THYME
    Officer
    $485,766
    @ $139.95 · 2026-09-01
    BANCEL STEPHANE J
    Chief Executive Officer
    $28.72M
    @ $57.52 · 2026-08-05
    HOGE STEPHEN
    President
    $3.61M
    @ $67.60 · 2026-07-15
    HOGE STEPHEN
    President
    $2.74M
    @ $51.37 · 2026-06-15
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    TXN
    1
    Sells (3M)
    28
    Sells (12M)
    Total value (12M): $114.87M
    ABRAHAM TSEDENIYA
    Officer
    $1.85M
    @ $264.63 · 2026-08-27
    CRAIGHEAD MARTIN S
    Director
    $3.20M
    @ $320.43 · 2026-05-28
    LIZARDI RAFAEL R
    Chief Financial Officer
    $14.71M
    @ $308.10 · 2026-05-14
    BAHAI AHMAD
    Officer
    $1.55M
    @ $309.13 · 2026-05-14
    COX CARRIE SMITH
    Director
    $2.71M
    @ $306.41 · 2026-05-13
    LEONARD SHANON J
    Officer
    $1.47M
    @ $295.22 · 2026-05-11
    ILAN HAVIV
    Chief Executive Officer
    $5.61M
    @ $280.32 · 2026-05-04
    KNECHT JULIE C.
    Officer
    $2.77M
    @ $278.70 · 2026-05-01
    GARY MARK
    Officer
    $3.82M
    @ $279.25 · 2026-04-30
    ROBERTS MARK T
    Officer
    $7.87M
    @ $280.34 · 2026-04-30
    YUNUS MOHAMMAD
    Officer
    $13.82M
    @ $270.44 · 2026-04-29
    KANE KATHARINE
    General Counsel
    $1.66M
    @ $270.41 · 2026-04-27
    BAHAI AHMAD
    Officer
    $982,359
    @ $268.40 · 2026-04-27
    RON AMICHAI
    Officer
    $5.00M
    @ $272.43 · 2026-04-24
    LIZARDI RAFAEL R
    Chief Financial Officer
    $11.12M
    @ $274.23 · 2026-04-24
    WITZSCHE CHRISTINE
    Officer
    $998,771
    @ $275.52 · 2026-04-24
    LEONARD SHANON J
    Officer
    $5.06M
    @ $277.95 · 2026-04-24
    PATSLEY PAMELA H
    Director
    $1.19M
    @ $276.11 · 2026-04-24
    BLUEDORN TODD M
    Director
    $1.18M
    @ $274.25 · 2026-04-24
    KOZANIAN HAGOP H
    Officer
    $1.55M
    @ $225.95 · 2026-02-17
    LIZARDI RAFAEL R
    Chief Financial Officer
    $15.88M
    @ $221.73 · 2026-02-11
    GARY MARK
    Officer
    $5.24M
    @ $226.00 · 2026-02-11
    BAHAI AHMAD
    Officer
    $1.50M
    @ $230.79 · 2026-02-11
    ROBERTS MARK T
    Officer
    $986,604
    @ $221.16 · 2026-02-09
    BLINN MARK A
    Director
    $696,647
    @ $221.58 · 2026-02-05
    BAHAI AHMAD
    Officer
    $670,387
    @ $223.46 · 2026-02-05
    KIRK RONALD
    Director
    $1.62M
    @ $162.33 · 2025-11-24
    WITZSCHE CHRISTINE
    Officer
    $164,306
    @ $164.31 · 2025-11-13
    BAHAI AHMAD
    Officer
    $308,030
    @ $205.35 · 2025-08-25
    TEMPLETON RICHARD K
    Chairman of the Board
    $19.85M
    @ $195.41 · 2025-02-28
    TEMPLETON RICHARD K
    Chairman of the Board
    $38.65M
    @ $199.20 · 2025-02-26
    TEMPLETON RICHARD K
    Chairman of the Board
    $39.32M
    @ $202.70 · 2025-02-24
    CLARK JANET F
    Director
    $1.23M
    @ $203.62 · 2025-02-24
    BLINN MARK A
    Director
    $1.17M
    @ $189.89 · 2025-02-19
    LEONARD SHANON J
    Officer
    $401,241
    @ $186.62 · 2025-02-18
    BLINN MARK A
    Director
    $106,617
    @ $180.71 · 2025-02-04
    KIRK RONALD
    Director
    $2.14M
    @ $203.33 · 2024-11-25
    ILAN HAVIV
    Chief Executive Officer
    $2.88M
    @ $219.30 · 2024-11-08
    GARY MARK
    Officer
    $3.49M
    @ $219.82 · 2024-11-08
    LIZARDI RAFAEL R
    Chief Financial Officer
    $10.19M
    @ $217.16 · 2024-11-07
    YUNUS MOHAMMAD
    Officer
    $1.81M
    @ $216.94 · 2024-11-07
    BAHAI AHMAD
    Officer
    $472,514
    @ $217.25 · 2024-11-07
    GARY MARK
    Officer
    $940,296
    @ $214.83 · 2024-11-06
    ILAN HAVIV
    Chief Executive Officer
    $5.29M
    @ $211.50 · 2024-11-06
    WITZSCHE CHRISTINE
    Officer
    $27,941
    @ $211.67 · 2024-11-06
    SANCHEZ ROBERT E
    Director
    $2.09M
    @ $208.80 · 2024-10-25
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    MRNA
    FearGreed
    😐Neutral(53/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    TXN
    FearGreed
    😐Neutral(49/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (53)
    TXN
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (49)
    View MRNA Full AnalysisView TXN Full Analysis

    Frequently Asked Questions: MRNA vs TXN

    Is Moderna, Inc. or Texas Instruments Incorporated more undervalued in 2026?

    Based on our discounted cash flow model, TXN trades at a 29.5% margin of safety (intrinsic value $365 vs. price $257), compared to MRNA's -135.0% margin of safety (intrinsic $67 vs. $156).

    Which stock has a wider economic moat, Moderna, Inc. or Texas Instruments Incorporated?

    TXN scores 48/100 (Narrow moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Moderna, Inc. in financial distress?

    MRNA's Altman Z-Score of 2.5 places it in the Grey zone, signaling elevated bankruptcy risk. TXN scores 8.7 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, Moderna, Inc. or Texas Instruments Incorporated?

    Texas Instruments Incorporated (TXN) generates a 1.5% free cash flow yield, compared to Moderna, Inc.'s 0.5%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, Moderna, Inc. or Texas Instruments Incorporated?

    TXN earns 20.4% ROIC versus MRNA's -122.0%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.